Although IL-1β, IL-6, and TNFα are well-established to influence nociceptive hypersensitivity, the possibility that additional or alternative mediators may also be driving nociceptive sensitivity in patients with COVID-19 cannot be discounted, especially in severe and critical infection. The gene discussed is TNF; the disease is COVID-19.